|Bid||43.92 x 1400|
|Ask||45.42 x 1200|
|Day's Range||42.72 - 45.30|
|52 Week Range||29.17 - 67.86|
|Beta (3Y Monthly)||0.25|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||75.89|
Biohaven Pharmaceuticals, which recently announced a positive Stage 3 trial for one of its migraine treatments. Dr. Vlad Coric, CEO of Biohaven, discusses the future of the drug and the company with Yahoo Finance's Alexis Christoforous and Brian Sozzi
NEW HAVEN, Conn., July 22, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, today announced that enrollment in the T2 Protect AD Study, a Phase 2/3 clinical trial of troriluzole in Alzheimer's disease, is progressing on timelines with more than 400 subjects enrolled (for screening) and over 180 subjects randomized to study treatment (troriluzole or placebo). The T2 Protect AD Study (clinicaltrials.gov identifier NCT03605667) is a Phase 2/3, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of troriluzole in patients diagnosed with Alzheimer's disease of mild-to-moderate severity (Mini-Mental State Examination scores of 14-24).
- Biohaven is already engaged with the FDA regarding next steps for a timely resolution of this matter and has submitted additional information to the Agency. -FDA cited issues with the active pharmaceutical ingredient (API) used in the Biohaven 2017 bioequivalence study that was manufactured between 2014 and 2016 in an Apotex facility. -Biohaven notes that the API for its commercial supply of Nurtec is sourced from another supplier, with whom there are no current issues.
NEW HAVEN, Conn., July 15, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) announces that The Lancet published online positive results from a Phase 3 pivotal clinical trial of rimegepant Zydis® orally dissolving tablet (ODT) for the acute treatment of migraine.
- Rimegepant Zydis® Oral Fast-Dissolve Tablet (ODT) Phase 3 results demonstrate rapid and sustained benefits for the acute treatment of migraine - Presentations also include: -New interim analyses from ...
-Research suggests patients define effective migraine therapies as reliable pain relief that enables them to return to their lives. Current treatments limit the ability for some patients to reach their treatment goals due to nonresponse to standard therapies and side effects. NEW HAVEN, Conn., July 11, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN), has launched a campaign called 'Demand More' highlighting what patients want and need from an acute treatment of migraine in their own words.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 10) CONMED Corporation (NASDAQ: CNMD ) Eidos Therapeutics ...
NEW HAVEN, Conn., July 10, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN), announced today that positive results from a Phase 3 pivotal clinical trial of rimegepant, Biohaven's small molecule calcitonin gene-related peptide (CGRP) receptor antagonist, for the acute treatment of migraine, are published in the July 12, 2019 issue of the New England Journal of Medicine (NEJM).
The contest was won by rookie Peter Alonso -- about the only good thing about the Mets season to this point. The stock fell some 30% in short order after announcing and executing a $300 million secondary offering to raise funding.
Trigeminal neuralgia is a neuropathic pain disorder characterized by recurrent, paroxysmal, lancinating pain in the distribution of one or more branches of the trigeminal nerve. These episodic bouts of severe facial pain can last seconds to minutes, occur several times per day, and often result in significant disability. The neuropeptide calcitonin gene-related peptide (CGRP) is thought to play an important role in the development of neuronal sensitization and neuropathic pain and its aberrant release from the trigeminal nerve has been implicated in the pathophysiology of trigeminal neuralgia.
CEO of Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Vlad Coric bought 5,000 shares of BHVN on 06/26/2019 at an average price of $40.22 a share.
-Rimegepant leads the meeting with the most presentations for an oral small molecule CGRP receptor antagonist, including 14 late breakers -Oral Presentation of rimegepant Zydis® Orally Dissolving Tablet ...
NEW HAVEN, Conn. , June 18, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a clinical‑stage biopharmaceutical company with a portfolio of innovative, late‑stage product ...
(Bloomberg Opinion) -- Biohaven Pharmaceutical Holding Co. has rapidly transformed from one of biotech’s darlings into a cautionary tale of overheated M&A hype. Shares of the developer of migraine treatments surged in April after Bloomberg News reported that the company was considering a sale; the stock then took another leg up earlier this month when Biohaven canceled plans to attend a Goldman Sachs health-care conference, fueling speculation a takeover was imminent. All those gains evaporated this week when the company instead announced that it was selling more shares, something that wouldn’t happen if a deal was in sight. As of midday Tuesday, the stock was down 35 percent from its highs: Biohaven’s ongoing single status shouldn’t have come as so much of a shock. The company has arguably never been as compelling an M&A target as some investors and analysts seem to think, and faces significant risks if it has to go it alone. Deal hype isn’t a self-fulfilling prophecy in biotech; in fact, it can sometimes backfire and result in the exact opposite. In the case of Biohaven, the company’s lead drug in development is a migraine pill that takes the same approach as a group of three recently approved injectable medicines that can help prevent the debilitating headaches. Biohaven's drug is a fast-acting alternative, but it will have to compete for a subset of the market with cheaper generic options and a direct rival from Allergan PLC.The drug’s tough path forward is one of the reasons Biohaven was likely open to a buyout; this launch will be even harder and slower without the financial resources and commercial expertise of a larger company. But that same dynamic is also potentially what’s keeping potential suitors away. Biohaven just isn’t the sort of company that pharma has been buying. The sweet spot of M&A in the industry has centered around cancer drugs and rare-disease treatments that command very high prices, partly by sidestepping the pricing and reimbursement problems that dog larger and more competitive markets such as the one for migraine remedies. Most recent biopharma acquisitions above $1.5 billion have been for companies working in these areas or for drugs that already generate sales. It’s possible that a drugmaker could decide to do something different, but it would need a compelling reason, and the hype-driven ascent of BioHaven’s valuation doesn’t help.This is pretty clearly a situation where takeover excitement got well ahead of reality, which isn’t uncommon in biotech. But context matters, and any investment thesis that depends on big pharma expensively bucking an M&A trend to get itself into a possible price war deserves some extra skepticism.To contact the author of this story: Max Nisen at firstname.lastname@example.orgTo contact the editor responsible for this story: Beth Williams at email@example.comThis column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Max Nisen is a Bloomberg Opinion columnist covering biotech, pharma and health care. He previously wrote about management and corporate strategy for Quartz and Business Insider.For more articles like this, please visit us at bloomberg.com/opinion©2019 Bloomberg L.P.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 17) ArQule, Inc. (NASDAQ: ARQL )( reported positive results ...
The simplest way to invest in stocks is to buy exchange traded funds. But you can significantly boost your returns by...
NEW HAVEN, Conn., June 17, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN), a clinical‑stage biopharmaceutical company with a portfolio of innovative, late‑stage product candidates targeting neurological diseases, including rare disorders, today announced that it has commenced an underwritten public offering of $300 million of its common shares. All of the common shares to be sold in the offering will be offered by Biohaven. In addition, Biohaven expects to grant the underwriters a 30-day option to purchase up to an additional $45 million of common shares at the public offering price, less underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
Alzheimer's treatment continues to confound biotech companies in the wake of Biogen and Eisai's decision to terminate two late-stage tests. But scientists say there's hope in new theories.
Hedge funds are not perfect. They have their bad picks just like everyone else. Facebook, a stock hedge funds have loved dearly, lost nearly 40% of its value at one point in 2018. Although hedge funds are not perfect, their consensus picks do deliver solid returns, however. Our data show the top 20 S&P 500 […]
Biohaven Pharmaceutical (BHVN) needs investors to pay close attention to the stock based on moves in the options market lately.
- Over 105,000 doses of rimegepant 75 mg have been administered in over 1,780 migraine patients in the long-term safety study to date - Safety profile remains favorable with no liver safety signal detected ...
- Phase 2/3 clinical trials of troriluzole, a glutamate modulator, in Alzheimer's disease, generalized anxiety disorder, and obsessive-compulsive disorder are all expected to complete enrollment by end ...